Background Autoantibodies against type I IFNs occur in approximately 10% of adults with
life-threatening coronavirus disease 2019 (COVID-19). The frequency of anti-IFN …

Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel
coronavirus that emerged recently and has created a global pandemic. Symptomatic SARS …

Background Inborn errors of immunity (IEI) and autoantibodies to type I interferons (IFNs)
underlie critical COVID-19 pneumonia in at least 15% of the patients, while the causes of …

Patients with antibody deficiency are at risk for bacterial and viral infections. 1, 2 Regular
immunoglobulin replacement therapy by intravenous or subcutaneous infusions reduces …

Background Most severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected
individuals are asymptomatic or only exhibit mild disease. In about 10% of cases, the …

A recent work published in Science by Paul Bastard et al. 1 reported that neutralizing auto-
antibodies (auto-Abs) against type I interferons (IFNs) were distinctly found in patients with …

Autoantibodies (AABs) neutralizing type I interferons (IFN) underlie about 15% of cases of
critical coronavirus disease 2019 (COVID-19) pneumonia. The impact of autoimmunity …

To the Editor, Bastard et al. reported that autoantibodies neutralizing type I interferons (IFN)
s are found in at least 18% of deceased COVID-19 patients [1]. They also showed that the …

Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with
APS-1 | Journal of Experimental Medicine | Rockefeller University Press Skip to Main Content …

Neutralizing autoantibodies against type I interferons (IFNs) have been found in some
patients with critical coronavirus disease 2019 (COVID-19), the disease caused by severe …